|
1
|
Fong Y, Fortner J, Sun RL, Brennan MF and
Blumgart LH: Clinical score for predicting recurrence after hepatic
resection of metastatic colorectal cancer: analysis of 1001
consecutive cases. Ann Surg. 230:309–318. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Galon J, Costes A, Sanchez-Cabo F, et al:
Type, density, and location of immune cells within colorectal
tumors predict clinical outcome. Science. 313:1960–1964. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ockert D, Schirrmacher V, Beck N, et al:
Newcastle disease virus-infected intact autologous tumor cell
vaccine for adjuvant active specific immunotherapy of resected
colorectal carcinoma. Clin Cancer Res. 2:21–28. 1996.
|
|
4
|
Schirrmacher V, Fournier P and Schlag P:
Autologous tumor cell vaccines for post-operative active-specific
immunotherapy of colorectal carcinoma: long-term patient survival
and mechanism of function. Exp Rev Vaccines. 13:117–130. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schulze T, Kemmner W, Weitz J, et al:
Efficiency of adjuvant active specific immunization with Newcastle
disease virus modified tumor cells in colorectal cancer patients
following resection of liver metastases: results of a prospective
randomized trial. Cancer Immunol Immunother. 58:61–69. 2009.
View Article : Google Scholar
|
|
6
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schwartz RH: T cell anergy. Annu Rev
Immunol. 21:305–334. 2003. View Article : Google Scholar
|
|
8
|
Greenfield EA, Nguyen KA and Kuchroo VK:
CD28/B7 costimulation: a review. Crit Rev Immunol. 18:389–418.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fournier P and Schirrmacher V: Bispecific
antibodies and trispecific immunocytokines for targeting the immune
system against cancer: preparing for the future. BioDrugs.
27:35–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aigner M, Janke M, Lulei M, Beckhove P,
Fournier P and Schirrmacher V: An effective tumor vaccine optimized
for costimulation via bispecific and trispecific fusion proteins.
Int J Oncol. 32:777–789. 2008.PubMed/NCBI
|
|
11
|
Haas C, Lulei M, Fournier P, Arnold A and
Schirrmacher V: T-cell triggering by CD3- and CD28-binding
molecules linked to a human virus-modified tumor cell vaccine.
Vaccine. 23:2439–2453. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Haas C, Lulei M, Fournier P, Arnold A and
Schirrmacher V: A tumor vaccine containing anti-CD3 and anti-CD28
bispecific antibodies triggers strong and durable antitumor
activity in human lymphocytes. Int J Cancer. 118:658–667. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Koch M, Beckhove P, Op den Winkel J, et
al: Tumor infiltrating T lymphocytes in colorectal cancer:
Tumor-selective activation and cytotoxic activity in situ. Ann
Surg. 244:986–992. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sommerfeldt N, Schütz F, Sohn C, Förster
J, Schirrmacher V and Beckhove P: The shaping of a polyvalent and
highly individual T-cell repertoire in the bone-marrow of breast
cancer patients. Cancer Res. 66:8258–8265. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Termeer CC, Schirrmacher V, Bröcker EB and
Becker JC: Newcastle disease virus infection induces
B7-1/B7-2-independent T-cell costimulatory activity in human
melanoma cells. Cancer Gene Ther. 7:316–323. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bai L, Koopmann J, Fiola C, Fournier P and
Schirrmacher V: Dendritic cells pulsed with viral oncolysates
potently stimulate autologous T cells from cancer patients. Int J
Oncol. 21:685–694. 2002.PubMed/NCBI
|
|
17
|
Brischwein K, Schlereth B, Guller B, et
al: MT110: a novel bispecific single-chain antibody construct with
high efficacy in eradicating established tumors. Mol Immunol.
43:1129–1143. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Biburger M, Weth R and Wels WS: A novel
bispecific tetravalent antibody fusion protein to target
costimulatory activity for T-cell activation to tumor cells
overexpressing ErbB2/HER2. J Mol Biol. 346:1299–1311. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Müller D, Frey K and Kontermann RE: A
novel antibody-4-1BBL fusion protein for targeted costimulation in
cancer immunotherapy. J Immunother. 31:714–722. 2008.PubMed/NCBI
|
|
20
|
Schirrmacher V, Haas C, Bonifer R, Ahlert
T, Gerhards R and Ertel C: Human tumor cell modification by virus
infection: an efficient and safe way to produce cancer vaccine with
pleiotropic immune stimulatory properties when using Newcastle
disease virus. Gene Ther. 6:63–73. 1999. View Article : Google Scholar
|
|
21
|
Fournier P, Wilden H and Schirrmacher V:
Importance of retinoic acid-inducible gene I and of receptor for
Type I interferon for cellular resistance to infection by Newcastle
disease virus. Int J Oncol. 40:287–298. 2012.PubMed/NCBI
|
|
22
|
Washburn B and Schirrmacher V: Human tumor
cell infection by Newcastle Disease Virus leads to upregulation of
HLA and cell adhesion molecules and to induction of interferons,
chemokines and finally apoptosis. Int J Oncol. 21:85–93. 2002.
|
|
23
|
Grakoui A, Bromley SK, Sumen C, et al: The
immunological synapse: a molecular machine controlling T cell
activation. Science. 285:221–227. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zitvogel L, Tesniere A and Kroemer G:
Cancer despite immunosurveillance: immunoselection and
immunosubversion. Nat Rev Immunol. 6:715–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
St Clair EW: The calm after the cytokine
storm: lessons from the TGN1412 trial. J Clin Invest.
118:1344–1347. 2008.PubMed/NCBI
|
|
26
|
Feuerer M, Beckhove P, Bai L, Solomayer
EF, Bastert G, Diehl IJ, Pedain C, Oberniedermayr M, Schirrmacher V
and Umansky V: Therapy of human tumors in NOD/SCID mice with
patient-derived reactivated memory T cells from bone marrow. Nat
Med. 7:452–458. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feuerer M, Beckhove P, Garbi N, Mahnke Y,
Limmer A, Hommel M, Hämmerling GJ, Kyewsky B, Hamann A, Umansly V
and Schirrmacher V: Bone marrow as a priming site for T-cell
responses to blood-borne antigen. Nat Med. 9:1151–1157. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schirrmacher V, Feuerer M, Fournier P,
Ahlert T, Umansky V and Beckhove P: T-cell priming in bone marrow:
the potential for long-lasting protective anti-tumor immunity.
Trends Mol Med. 9:526–534. 2003. View Article : Google Scholar : PubMed/NCBI
|
